MATRIKS METALOPROTEINAZE ‒ VAŽNI UČESNICI U SVAKOM KORAKU RAZVOJA TUMORA I OBEĆAVAJUĆE METE U SAVREMENOJ ANTITUMORSKOJ TERAPIJI
Sažetak
Matriks metaloproteinaze su proteolitički enzimi koji mogu da razgrađuju skoro sve komponente ekstracelularnog matriksa, kao i mnoge druge solubilne i membranske molekule različite prirode. Njihova proteolitička aktivnost veoma je značajna za embriogenezu, razvoj, remodelovanje i organizaciju tkiva. Osim što su veoma značajne za odvijanje fizioloških procesa, imaju i veoma važnu ulogu u razvoju i progresiji tumorskog procesa, tkivnoj invaziji i metastaziranju tumora.
U ovom preglednom članku razmatramo kompleksno učešće ovih endopeptidaza zavisnih od cinka u svakom koraku razvoja i progresije tumorskog procesa. Posebno ističemo značaj saradnje između tumorskih ćelija i njihove mikrookoline na različitim nivoima razvoja i širenja tumorskog procesa. Takođe, naglašavamo značaj inhibicije pojedinih matriks metaloproteinaza (u zavisnosti od vrste i stadijuma tumora) u cilju podrške citostatskoj terapiji.
Reference
Acuff HB, Carter KJ, Fingleton B, Gorden DL, Matrisian LM. Matrix metalloproteinase-9 from bone marrow-derived cells contributes to survival but not growth of tumor cells in the lung microenvironment. Cancer Res.2006;66(1):259-66. [CrossRef] [PubMed]
Arroyo AG, Genís L, Gonzalo P, Matías-Román S, Pollán A, Gálvez BG. Matrix metalloproteinases: new routes to the use of MT1-MMP as a therapeutic target in angiogenesis-related disease. Curr Pharm Des 2007; 13(17): 1787-802. [CrossRef] [PubMed]
Azevedo Martins JM, Rabelo-Santos SH, do Amaral Westin MC, Zeferino LC. Tumoral and stromal expression of MMP-2, MMP-9, MMP-14, TIMP-1, TIMP-2, and VEGF-A in cervical cancer patient survival: a competing risk analysis. BMC Cancer 2020;20(1):660. [CrossRef] [PubMed]
Blanco MJ, Rodríguez-Martín I, Learte AIR, Clemente C, Montalvo MG, Seiki M et al. Developmental expression of membrane type 4-matrix metalloproteinase (Mt4-mmp/Mmp17) in the mouse embryo. PLoS One 2017;12(9):e0184767. [CrossRef] [PubMed]
Cabral-Pacheco GA, Garza-Veloz I, Castruita-De la Rosa C, Ramirez-Acuña JM, Perez-Romero BA, Guerrero-Rodriguez JF et al. The Roles of Matrix Metalloproteinases and Their Inhibitors in Human Diseases. Int J Mol Sci 2020;21(24):9739. [CrossRef] [PubMed]
De Vicente JC, Lequerica-Fernández P, Santamaría J, Fresno MF. Expression of MMP-7 and MT1-MMP in oral squamous cell carcinoma as predictive indicator for tumor invasion and prognosis. J Oral Pathol Med 2007; 36(7): 415-24. [CrossRef] [PubMed]
Eiden C, Ungefroren H. The Ratio of RAC1B to RAC1 Expression in Breast Cancer Cell Lines as a Determinant of Epithelial/Mesenchymal Differentiation and Migratory Potential. Cells 2021;10(2):351. [CrossRef] [PubMed]
Escaff S, Fernández JM, González LO, Suárez A, González-Reyes S, González JM et al. Study of matrix metalloproteinases and their inhibitors in prostate cancer. Br J Cancer 2010; 102(5): 922-9. [CrossRef] [PubMed]
Falconer RA, Loadman PM. Membrane-type matrix metalloproteinases: expression, roles in metastatic prostate cancer progression and opportunities for drug targeting. J Cancer Metastasis Treat 2017;3:315-27. [CrossRef]
Genís L, Gálvez BG, Gonzalo P, Arroyo AG. MT1-MMP: universal or particular player in angiogenesis? Cancer Metastasis Rev 2006; 25(1):77-86. [CrossRef] [PubMed]
Giavazzi R, Garofalo A, Ferri C, Lucchini V, Bone EA, Chiari S et al. Batimastat, a synthetic inhibitor of matrix metalloproteinases, potentiates the antitumor activity of cisplatin in ovarian carcinoma xenografts. Clin Cancer Res. 1998; 4(4):985-92. [PubMed]
Gill JH, Kirwan IG, Seargent JM, Martin SW, Tijani S, Anikin VA et al. MMP-10 is overexpressed, proteolytically active, and a potential target for therapeutic intervention in human lung carcinomas. Neoplasia 2004; 6(6):777-85. [CrossRef] [PubMed]
Gong Y, Chippada-Venkata UD, Oh WK. Roles of matrix metalloproteinases and their natural inhibitors in prostate cancer progression. Cancers (Basel) 2014; 6(3): 1298-327. [CrossRef] [PubMed]
Holland JD, Klaus A, Garratt AN, Birchmeier W. Wnt signaling in stem and cancer stem cells. Curr Opin Cell Biol 2013;25(2):254-64. [CrossRef] [PubMed]
Jobin PG, Butler GS, Overall CM. New intracellular activities of matrix metalloproteinases shine in the moonlight. Biochim Biophys Acta Mol Cell Res 2017;1864(11 Pt A):2043-55. [CrossRef] [PubMed]
Kaszak I, Witkowska-Piłaszewicz O, Niewiadomska Z, Dworecka-Kaszak B, Ngosa Toka F, Jurka P. Role of Cadherins in Cancer-A Review. Int J Mol Sci 2020;21(20):7624. [CrossRef] [PubMed]
Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 2010;141(1):52-67. [CrossRef] [PubMed]
Kessenbrock K, Wang CY, Werb Z. Matrix metalloproteinases in stem cell regulation and cancer. Matrix Biol 2015;44-46:184-90. [CrossRef] [PubMed]
Khan YH, Uttra AM, Qasim S, Mallhi TH, Alotaibi NH, Rasheed M, et al. Potential Role of Phytochemicals Against Matrix Metalloproteinase Induced Breast Cancer; An Explanatory Review. Front Chem 2021; 8:592152. [CrossRef] [PubMed]
Ko JH, Sethi G, Um JY, Shanmugam MK, Arfuso F, Kumar AP et al. The Role of Resveratrol in Cancer Therapy. Int J Mol Sci 2017;18(12):2589. [CrossRef] [PubMed]
Kolijn K, Verhoef EI, van Leenders GJ. Morphological and immunohistochemical identification of epithelial-to-mesenchymal transition in clinical prostate cancer. Oncotarget 2015;6(27):24488-98. [CrossRef] [PubMed]
Lang SH, Frame FM, Collins AT. Prostate cancer stem cells. J Pathol 2009;217(2):299-306. [CrossRef] [PubMed]
Li S, Pritchard DM, Yu L-G. Regulation and Function of Matrix Metalloproteinase-13 in Cancer Progression and Metastasis. Cancers 2022; 14(13):3263. [CrossRef] [PubMed]
Liu H, Kato Y, Erzinger SA, Kiriakova GM, Qian Y, Palmieri D, et al. The role of MMP-1 in breast cancer growth and metastasis to the brain in a xenograft model. BMC Cancer 2012; 12: 583. [CrossRef] [PubMed]
Liu J, Khalil RA. Matrix Metalloproteinase Inhibitors as Investigational and Therapeutic Tools in Unrestrained Tissue Remodeling and Pathological Disorders. Prog Mol Biol Transl Sci 2017; 148: 355-420. [CrossRef] [PubMed]
Liu J, Khalil RA. Matrix Metalloproteinase Inhibitors as Investigational and Therapeutic Tools in Unrestrained Tissue Remodeling and Pathological Disorders. Prog Mol Biol Transl Sci 2017;148:355-420. [CrossRef] [PubMed]
Mannello F, Tonti GA, Bagnara GP, Papa S. Role and function of matrix metalloproteinases in the differentiation and biological characterization of mesenchymal stem cells. Stem Cells 2006;24(3):475-81. [CrossRef] [PubMed]
Mariya T, Hirohashi Y, Torigoe T, Tabuchi Y, Asano T, Saijo H et al. Matrix metalloproteinase-10 regulates stemness of ovarian cancer stem-like cells by activation of canonical Wnt signaling and can be a target of chemotherapy-resistant ovarian cancer. Oncotarget 2016; 7(18): 26806-22. [CrossRef] [PubMed]
Maybee DV, Ink NL, Ali MAM. Novel Roles of MT1-MMP and MMP-2: Beyond the Extracellular Milieu. Int J Mol Sci 2022;23(17):9513. [CrossRef] [PubMed]
Melzer C, Hass R, Lehnert H, Ungefroren H. RAC1B: A Rho GTPase with Versatile Functions in Malignant Transformation and Tumor Progression. Cells.2019;8(1):21. [CrossRef] [PubMed]
Méndez-López LF. Revisiting Epithelial Carcinogenesis. Int J Mol Sci. 2022; 23(13):7437. [CrossRef] [PubMed]
Muñoz-Sáez E, Moracho N, Learte AIR, Arroyo AG, Sánchez-Camacho C. Dynamic Expression of Membrane Type 1-Matrix Metalloproteinase (Mt1-mmp/Mmp14) in the Mouse Embryo. Cells 2021;10(9):2448. [CrossRef] [PubMed]
Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM. Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol 2000;18(5):1135-49. [CrossRef] [PubMed]
Palavalli LH, Prickett TD, Wunderlich JR, Wei X, Burrell AS, Porter-Gill P et al. Analysis of the matrix metalloproteinase family reveals that MMP8 is often mutated in melanoma. Nat Genet 2009;41(5):518-20. [CrossRef] [PubMed]
Pang L, Li Q, Li S, He J, Cao W, Lan J et al. Membrane type 1-matrix metalloproteinase induces epithelial-to-mesenchymal transition in esophageal squamous cell carcinoma: Observations from clinical and in vitro analyses. Sci Rep 2016;6: 22179. [CrossRef] [PubMed]
Piskór BM, Przylipiak A, Dąbrowska E, Niczyporuk M, Ławicki S. Matrilysins and Stromelysins in Pathogenesis and Diagnostics of Cancers. Cancer Manag Res 2020; 12: 10949-64. [CrossRef] [PubMed]
Quintero-Fabián S, Arreola R, Becerril-Villanueva E, Torres-Romero JC, Arana-Argáez V, Lara-Riegos J et al. Role of Matrix Metalloproteinases in Angiogenesis and Cancer. Front Oncol 2019; 9: 1370. [CrossRef] [PubMed]
Radisky DC, Bissell MJ. Matrix metalloproteinase-induced genomic instability. Curr Opin Genet Dev 2006;16(1):45-50. [CrossRef] [PubMed]
Radisky DC, Levy DD, Littlepage LE, Liu H, Nelson CM, Fata JE et al. Rac1b and reactive oxygen species mediate MMP-3-induced EMT and genomic instability. Nature 2005;436(7047):123-7. [CrossRef] [PubMed]
Radisky ES, Raeeszadeh-Sarmazdeh M, Radisky DC. Therapeutic Potential of Matrix Metalloproteinase Inhibition in Breast Cancer. J Cell Biochem 2017;118(11):3531-48. [CrossRef] [PubMed]
Rydlova M, Holubec L Jr, Ludvikova M Jr, Kalfert D, Franekova J, Povysil C et al. Biological activity and clinical implications of the matrix metalloproteinases. Anticancer Res 2008;28(2B):1389-97. [PubMed]
Sarper M, Allen MD, Gomm J, Haywood L, Decock J, Thirkettle S et al. Loss of MMP-8 in ductal carcinoma in situ (DCIS)-associated myoepithelial cells contributes to tumour promotion through altered adhesive and proteolytic function. Breast Cancer Res 2017;19(1):33. [CrossRef] [PubMed]
Sawey ET, Johnson JA, Crawford HC. Matrix metalloproteinase 7 controls pancreatic acinar cell transdifferentiation by activating the Notch signaling pathway. Proc Natl Acad Sci U S A 2007;104(49):19327-32. [CrossRef] [PubMed]
Silk N, Reich J, Sinha R, Chawla S, Geary K, Zhang D. The Effects of Resveratrol on Prostate Cancer through Targeting the Tumor Microenvironment. J Xenobiot 2021;11(1):16-32. [CrossRef] [PubMed]
Song Y, Ye M, Zhou J, Wang ZW, Zhu X. Restoring E-cadherin Expression by Natural Compounds for Anticancer Therapies in Genital and Urinary Cancers. Mol Ther Oncolytics 2019;14:130-138. [CrossRef] [PubMed]
Sun Y, Jing J, Xu H, Xu L, Hu H, Tang C et al. N-cadherin inhibitor creates a microenvironment that protect TILs from immune checkpoints and Treg cells. J Immunother Cancer 2021;9(3):e002138. [CrossRef] [PubMed]
Verma D, Zanetti C, Godavarthy PS, Kumar R, Minciacchi VR, Pfeiffer J et al. Bone marrow niche-derived extracellular matrix-degrading enzymes influence the progression of B-cell acute lymphoblastic leukemia. Leukemia 2020; 34(6):1540-52. [CrossRef] [PubMed]
Wang X, Page-McCaw A. A matrix metalloproteinase mediates long-distance attenuation of stem cell proliferation. J Cell Biol 2014;206(7):923-36. [CrossRef] [PubMed]
Yosef G, Arkadash V, Papo N. Targeting the MMP-14/MMP-2/integrin αvβ3 axis with multispecific N-TIMP2-based antagonists for cancer therapy. J Biol Chem 2018; 293(34): 13310-26. [CrossRef] [PubMed]
Yu XF, Han ZC. Matrix metalloproteinases in bone marrow: roles of gelatinases in physiological hematopoiesis and hematopoietic malignancies. Histol Histopathol 2006; 21(5): 519-31. [CrossRef] [PubMed]